
Adam I Marcus

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7412563/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Vimentin Is Required for Lung Adenocarcinoma Metastasis via Heterotypic Tumor Cell–Cancer-Associated Fibroblast Interactions during Collective Invasion. Clinical Cancer Research, 2018, 24, 420-432.	7.0	175
2	The OncoPPi network of cancer-focused protein–protein interactions to inform biological insights and therapeutic strategies. Nature Communications, 2017, 8, 14356.	12.8	151
3	Mitotic Kinesin Inhibitors Induce Mitotic Arrest and Cell Death in Taxol-resistant and -sensitive Cancer Cells. Journal of Biological Chemistry, 2005, 280, 11569-11577.	3.4	149
4	The Synergistic Combination of the Farnesyl Transferase Inhibitor Lonafarnib and Paclitaxel Enhances Tubulin Acetylation and Requires a Functional Tubulin Deacetylase. Cancer Research, 2005, 65, 3883-3893.	0.9	101
5	FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells. Oncotarget, 2015, 6, 4757-4772.	1.8	101
6	Simultaneous Activation of Induced Heterodimerization between CXCR4 Chemokine Receptor and Cannabinoid Receptor 2 (CB2) Reveals a Mechanism for Regulation of Tumor Progression. Journal of Biological Chemistry, 2016, 291, 9991-10005.	3.4	73
7	uPAR-targeted Optical Imaging Contrasts as Theranostic Agents for Tumor Margin Detection. Theranostics, 2014, 4, 106-118.	10.0	69
8	LKB1 Regulated Pathways in Lung Cancer Invasion and Metastasis. Journal of Thoracic Oncology, 2010, 5, 1883-1886.	1.1	63
9	Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers. Oncotarget, 2016, 7, 43124-43149.	1.8	52
10	Epigenetically heterogeneous tumor cells direct collective invasion through filopodia-driven fibronectin micropatterning. Science Advances, 2020, 6, eaaz6197.	10.3	41
11	Targeting adhesion signaling in KRAS, LKB1 mutant lung adenocarcinoma. JCI Insight, 2017, 2, e90487.	5.0	36
12	LKB1 tumor suppressor: Therapeutic opportunities knock when LKB1 is inactivated. Genes and Diseases, 2014, 1, 64-74.	3.4	34
13	A role for activated Cdc42 in glioblastoma multiforme invasion. Oncotarget, 2016, 7, 56958-56975.	1.8	32
14	Local alignment vectors reveal cancer cell-induced ECM fiber remodeling dynamics. Scientific Reports, 2017, 7, 39498.	3.3	30
15	LKB1 kinase-dependent and -independent defects disrupt polarity and adhesion signaling to drive collagen remodeling during invasion. Molecular Biology of the Cell, 2016, 27, 1069-1084.	2.1	26
16	Genetic heterogeneity within collective invasion packs drives leader and follower cell phenotypes. Journal of Cell Science, 2019, 132, .	2.0	23
17	Aberrant Promoter Methylation of Caveolin-1 Is Associated with Favorable Response to Taxane-Platinum Combination Chemotherapy in Advanced NSCLC. PLoS ONE, 2014, 9, e107124.	2.5	21
18	Re-expression of LKB1 in LKB1-mutant EKVX cells leads to resistance to paclitaxel through the up-regulation of MDR1 expression. Lung Cancer, 2015, 88, 131-138.	2.0	11

Adam I Marcus

#	Article	IF	CITATIONS
19	Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer. Lung Cancer, 2018, 123, 36-43.	2.0	11
20	Leflunomide Suppresses the Growth of LKB1-Inactivated Tumors in the Immune-Competent Host and Attenuates Distant Cancer Metastasis. Molecular Cancer Therapeutics, 2021, 20, 274-283.	4.1	9
21	Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models. PLoS ONE, 2019, 14, e0206309.	2.5	7
22	LKB1 promotes cell survival by modulating TIF-IA-mediated pre-ribosomal RNA synthesis under uridine downregulated conditions. Oncotarget, 2016, 7, 2519-2531.	1.8	7
23	RhoA, a novel tumor suppressor or oncogene as a therapeutic target?. Genes and Diseases, 2015, 2, 2-3.	3.4	5
24	Energizing the Search to Target LKB1-Mutant Tumors. Cancer Discovery, 2013, 3, 843-845.	9.4	2